Zacks Investment Research downgraded shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) from a buy rating to a hold rating in a research report report published on Wednesday morning.
According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
A number of other research analysts have also weighed in on the stock. ValuEngine raised shares of Neos Therapeutics from a strong sell rating to a sell rating in a research report on Tuesday, June 20th. BMO Capital Markets reissued an outperform rating and set a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, June 20th. Finally, Cowen and Company assumed coverage on shares of Neos Therapeutics in a research report on Wednesday, April 5th. They set an outperform rating and a $20.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $13.00.
Shares of Neos Therapeutics (NASDAQ:NEOS) traded up 1.46% during mid-day trading on Wednesday, hitting $6.95. The stock had a trading volume of 137,514 shares. Neos Therapeutics has a 52 week low of $4.85 and a 52 week high of $9.65. The stock’s market cap is $156.79 million. The stock has a 50-day moving average price of $7.62 and a 200 day moving average price of $6.90.
Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Tuesday, May 9th. The company reported ($0.87) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.94) by $0.07. The firm had revenue of $5.63 million during the quarter. Neos Therapeutics had a negative net margin of 719.86% and a negative return on equity of 512.10%. On average, equities analysts forecast that Neos Therapeutics will post ($3.24) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://transcriptdaily.com/2017/07/20/neos-therapeutics-inc-neos-downgraded-to-hold-at-zacks-investment-research.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Mission Wealth Management LLC bought a new position in Neos Therapeutics during the first quarter valued at about $122,000. Teachers Advisors LLC increased its position in Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock valued at $149,000 after buying an additional 3,572 shares during the last quarter. Sheaff Brock Investment Advisors LLC bought a new position in Neos Therapeutics during the first quarter valued at about $216,000. Wells Fargo & Company MN increased its position in Neos Therapeutics by 130.3% in the first quarter. Wells Fargo & Company MN now owns 48,030 shares of the company’s stock valued at $346,000 after buying an additional 27,174 shares during the last quarter. Finally, Hunter Associates Investment Management LLC bought a new position in Neos Therapeutics during the first quarter valued at about $360,000. Institutional investors own 33.08% of the company’s stock.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.